TAMPERE, Finland, Sept. 8, 2022 /PRNewswire/ — The European Patent Workplace has introduced to approve Bioretec Oy’s hybrid composite materials patent utility EP3782657A1 and can grant and publish the patent after the Firm’s affirmation.
Accredited patent considerations magnesium-based bolstered composite materials, i.e., hybrid composite. The patent additionally contains the utilization of the hybrid composite materials within the manufacturing of a medical system or part of such a tool.
The patented hybrid composite materials shall be utilized in these merchandise of Bioretec’s RemeOs™ product household that require very excessive load-bearing capability. Focused purposes embody intramedullary nails within the lengthy bones of the higher and decrease extremities and implants for spinal fusion. The hybrid composite materials biodegrades within the physique equally because the RemeOs™ magnesium alloy materials and is changed by bone whereas selling fracture therapeutic, thus eliminating the necessity for implant elimination surgical procedure.
The patent utility course of for the hybrid composite materials in areas exterior of Europe continues primarily based on the worldwide PCT patent utility WO2021032882A1 and the Firm will inform about patent approvals in different areas as the appliance course of progress.
Additional enquiries Timo Lehtonen, CEO, p. +358 50 433 8493 Johanna Salko, CFO, p. +358 40 754 8172
Details about Bioretec Bioretec is a globally working Finnish medical system firm that continues to pioneer the appliance of bioresorbable orthopedic implants. The corporate has constructed distinctive competencies within the organic interface of energetic implants to boost bone progress and speed up fracture therapeutic after orthopedic surgical procedure. The merchandise developed and manufactured by Bioretec are used worldwide in roughly 40 nations.
Bioretec is creating the brand new RemeOs™ product line primarily based on a magnesium alloy and hybrid composite, introducing a brand new technology of robust bioresorbable supplies for enhanced surgical outcomes. The RemeOs™ implants are resorbed and changed by bone, which eliminates the necessity for elimination surgical procedure whereas facilitating fracture therapeutic. The mixture has the potential to make titanium implants redundant and assist clinics attain their Worth-Primarily based Healthcare targets whereas specializing in worth for sufferers by way of environment friendly healthcare. With the U.S. and EU market authorization for the primary RemeOs™ product anticipated in 2022, Bioretec is positioning itself to enter the addressable USD 7 billion international orthopedic trauma market and change into a recreation changer in surgical prospects.
Higher Therapeutic – Higher Life. www.bioretec.com.
This data was dropped at you by Cision http://information.cision.com